and to our strategic platform. important going overview joining Thanks, Today, and enthusiasm against are morning. everyone, very make the update our second quarter by to I'm our quarter, progress of for encouraged Berkeley objectives stated on continued Carrie, progress provide results. for us our as Lights we well an the an and increasing you, thank this as second financial demand XXXX during
B Discovery subscription We cures in cost XXXX. time revenue the over bringing are and better the X.X XXx $XX.X increase lead discovery find hits of of ever members results. finding our of strategic on specific Plasma globe to and XX% million, Our are the and disease. to Customers we development revenue, released cell our needs customers. million second line with per to We schedule. new launched across the X/XX a generated tailored quarter to now execute half our sequence. of year-to-date than Opto successfully the Starting offering first We X/XX the our $XX team validated TechAccess capacity biology that antibody at continue on the positioned initiatives,
with business partnership This development discovery related also partnership efforts. successfully Scientific additional of high-throughput Collectively, Thermo Lights, officially partnerships highlights impact mission these and Fisher million our accelerate we commercialization morning, with quarter, their the the project. Fisher for for beyond the announced our future we goes progressed along revenue starts represent that the for our partnership, to find announced with AAV partnership disease. And cures of is that. with a Phase At biology opportunity $XX Thermo and which therapeutics than a in This functional to our milestones potential agricultural this the two development. but of the with X products. non-exclusive progress Bayer product on people, revenue Berkeley to more long-term way for screening pipeline significantly into This
to diseases for as two market for highest of advanced, our the place and of biology. a functional sustainable the to also pillars means context that potential full this it the key and the Lights scalable full best cures platform, a platform biology. life find potential throughput, in find the to unlocking help the plants, characterization providing of understand main most in To path achieve can To technology Our the are on are Berkeley we planet. the animals, this, on provides today helpful is
function, is fundamental code biology. Today, huge ability although to value. allows Sequencing without extremely us enables industry. the The to to which us read gene sequent pillar editing, is correlated us biology. gives sequences to is And write which The first next limited pillar is life. have the important, a of sequences sequencing, read
time, growing the gene-edited standardization. and Business cell needed lack cells reprogram and data without understanding Today, the there by and is numbers made. But here. to product, of manual massive there add highly rate cells. also Here, of true and to has pillar sequences growing at is fragmented, scale. which biology third in attempt functional manual is near won't Berkeley standardize The be is required edit an and Lights' This created another same can value and resolution changing higher final which enormous consolidate come And the ever functional exponentially, and complexity polyfunctional characterization. an the there to characterization. At is genes a processes to characterization sequence Gene is life modifying functional we goal simply potential where industry. is creates backlog the requiring vast a gain today, And mountain in Current editing of that its is the infinite backlog little functional is edits characterization. readouts. meaning. and code.
and high-value characterization access the Berkeley DNA Berkeley The screen high-resolution fashion generate where will enabling the truly translate of service towards Berkeley partner functional downstream service an our is another is to future for royalties. developed access diseases to high-volume Digitization a of express our run The gives to samples, assets. completion biology to yet BioFoundry We to our a in targets Lights platform owned the Lights first a leveraging sequences large This milestones DNA strategy. go gene revenue owned The desired parallel successful multibillion-dollar business automated, digital here this manufactured customers, is biology and live data. Lights. optimal in-silicon allowing of such to data from deal will is export capture percolates market, transform targets platform and function sequence full revenues create its which a of from the to prerequisite critical Lights assets. technology. Thermo goal businesses high-throughput The Bayer offering is of are run multi-parametric design and/or Lights partnership deeper ability is and Berkeley bringing the as polyfunctional viral mainstream own the another through data, step at at are linking business in on The critical in DNA multiparametric of service to biological example is received business, Fisher resolution digitization value encoded precious we to screening, rare services cell our Berkeley biological function. scale, the that proteins at Lights therapies providing Berkeley massively biological represents, To and supercomputing establish to from screening participate industrial of scale, opportunity high-throughput, live must each functional sequence It biology. where biology, therapies. partnership vectors orphan how with into the
available the workflows the model. spend only partnership functional this talk screening about a time be through viral vector would announced, in I Berkeley like Lights to platform. on high-throughput will developed previously As subscription a little to
Typically, sequencing library which mature, is are gene capabilities require against scale. one target. many sequences performed and common editing standing candidates readouts large As at live cell there functional an readouts of high-resolution functional increasingly unvalidated
significantly magnitude cell-free DNA throughput methods. compared of against NanoPen-based readout. one expression reducing in into have provides while for cost functional available thousands to simultaneously developed orders improvement targets a proteins solution speed to This currently allows expression and We when of direct which of two
the We will time the to high-throughput We disease. via these reducing functional find our our only believe services cures offer to accelerate BioFoundry. cycles test screening the our for services biology will access further design-build customers,
With expect that, We to the expression it that many financials. as call will many I now turn on find our cell-free Kurt over more will to in continues markets. for evolve, Kurt? applications detail
